Skip to main content

Advertisement

Table 2 The clinical characteristics of the 403 non-small cell lung cancer (NSCLC) patients

From: Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

Variate Total Overall toxicity Hematological toxicity Hepatotoxicity Gastrointestinal toxicity Responsea
Grade 0–2 Grade 3–4 Grade 0–2 Grade 3–4 Grade 0–2 Grade 3–4 Grade 0–2 Grade 3–4 CR + PR SD + PD
All 403 268 (66.5) 135 (33.5) 308 (76.4) 95 (23.6) 348 (86.4) 55 (13.6) 368 (91.3) 35 (8.7) 115 (29.1) 280 (70.9)
Age (years)
 ≤55 176 (43.7) 114 (42.5) 62 (45.9) 139 (45.1) 37 (38.9) 144 (41.4) 32 (58.2) 156 (42.4) 20 (57.1) 54 (47.0) 118 (42.1)
 >55 227 (56.3) 154 (57.5) 73 (54.1) 169 (54.9) 58 (61.1) 204 (58.6) 23 (41.8) 212 (57.6) 15 (42.9) 61 (53.0) 162 (57.9)
Smoking status
 Never 170 (42.2) 107 (39.9) 63 (46.7) 131 (42.5) 39 (41.1) 142 (40.8) 28 (50.9) 154 (41.8) 16 (45.7) 46 (40.0) 119 (42.5)
 Ever 233 (57.8) 161 (60.1) 72 (53.3) 177 (57.5) 56 (58.9) 206 (59.2) 27 (49.1) 214 (58.2) 19 (54.3) 69 (60.0) 161 (57.5)
Sex
 Male 307 (76.2) 214 (79.9) 93 (68.9) 240 (77.9) 67 (70.5) 269 (77.3) 38 (69.1) 286 (71.7) 21 (60.0) 90 (78.3) 213 (76.1)
 Female 96 (23.8) 54 (20.1) 42 (31.1) 68 (22.1) 28 (29.5) 79 (22.7) 17 (30.9) 82 (22.3) 14 (40.0) 25 (21.7) 67 (23.9)
Eastern cooperative oncology group (ECOG) performance status
 0–1 380 (94.3) 255 (95.2) 125 (92.6) 290 (94.2) 90 (94.7) 329 (94.5) 51 (92.7) 348 (94.6) 32 (91.4) 110 (95.7) 263 (93.9)
 2 23 (5.7) 13 (4.8) 10 (7.4) 18 (5.8) 5 (5.3) 19 (5.5) 4 (7.3) 20 (5.4) 3 (8.6) 5 (4.3) 17 (6.1)
Histological type
 Adenocarcinoma 217 (53.8) 144 (53.7) 73 (54.1) 180 (58.4) 37 (38.9) 186 (53.4) 31 (56.4) 198 (53.8) 19 (54.3) 68 (59.1) 115 (41.1)
 Squamous cell 186 (46.2) 124 (46.3) 62 (45.9) 128 (41.6) 58 (61.1) 162 (46.6) 24 (43.6) 170 (46.2) 16 (45.7) 47 (40.9) 165 (58.9)
TNM stage
 I–II 9 (2.2) 7 (2.6) 2 (1.5) 7 (2.3) 2 (2.1) 9 (2.6) 0 (0.0) 8 (2.2) 1 (2.9) 2 (1.7) 7 (2.5)
 III–IV 394 (97.8) 261 (97.4) 133 (98.5) 301 (97.7) 93 (97.9) 339 (97.4) 55 (100.0) 360 (97.8) 34 (97.1) 113 (98.3) 273 (97.5)
Platinum-based drug
 Cisplatin 333 (82.6) 222 (82.8) 111 (82.2) 255 (82.8) 78 (82.1) 284 (81.6) 49 (89.1) 302 (82.1) 31 (88.6) 99 (86.1) 229 (81.8)
 Carboplatin 70 (17.4) 46 (17.2) 24 (17.8) 53 (17.2) 17 (17.9) 64 (18.4) 6 (10.9) 66 (17.9) 4 (11.4) 16 (13.9) 51 (18.2)
Chemotherapy regimen
 Platinum-gemcitabine 196 (48.6) 119 (44.4) 77 (57.0) 131 (42.5) 65 (68.4) 168 (48.3) 28 (50.9) 179 (48.6) 17 (48.6) 73 (63.5) 120 (42.8)
 Platinum-pemetrexed 148 (36.7) 105 (39.2) 43 (31.9) 127 (41.2) 21 (22.1) 130 (37.4) 18 (32.7) 133 (36.1) 15 (42.8) 27 (23.5) 117 (41.8)
 Platinum-paclitaxel 35 (8.7) 27 (10.1) 8 (5.9) 30 (9.8) 5 (5.3) 30 (8.6) 5 (9.1) 33 (9.0) 2 (5.7) 9 (7.8) 26 (9.3)
 Platinum-docetaxel 20 (5.0) 14 (5.2) 6 (4.5) 17 (5.5) 3 (3.2) 16 (4.6) 4 (7.3) 19 (5.2) 1 (2.9) 4 (3.5) 15 (5.4)
 Platinum-navelbine 4 (1.0) 3 (1.1) 1 (0.7) 3 (1.0) 1 (1.0) 4 (1.1) 0 (0.0) 4 (1.1) 0 (0.0) 2 (1.7) 2 (0.7)
  1. All data are presented as the number of patients with percentage in parentheses
  2. CR complete response, PR partial response, PD progressive disease, SD stable disease
  3. aThe assessment information of 8 patients were lost in the process of sample collection